ArticleNeurobiology of disease2013
Cuprizone short-term exposure: astrocytic IL-6 activation and behavioral changes relevant to psychosis.
Article in Neurobiology of disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 68 citations in OpenAlex.
- Glucosamine/chitosan blend surface-engineered rutin-loaded polymer/lipid hybrid nanoparticles for neuroprotection in induced schizophrenia model.Scientific reports · 2026Article
- Nuclear GAPDH in cortical microglia mediates cellular stress-induced cognitive inflexibility.Molecular psychiatry · 2024Article
- Interleukin-6 Inhibits Expression of miR-204-5p, a Regulator of Oligodendrocyte Differentiation: Involvement of miR-204-5p in the Prevention of Chemical-Induced Oligodendrocyte Impairment.Molecular neurobiology · 2024Article
- How to Use the Cuprizone Model to Study De- and Remyelination.International journal of molecular sciences · 2024Review
- Evidence for decreased copper associated with demyelination in the corpus callosum of cuprizone-treated mice.Metallomics : integrated biometal science · 2024Article
- Astrocytes: Lessons Learned from the Cuprizone Model.International journal of molecular sciences · 2023Review
- Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice.Molecular brain · 2023Article
- The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia.Translational psychiatry · 2022Review
- Effects of Axonal Demyelination, Inflammatory Cytokines and Divalent Cation Chelators on Thalamic HCN Channels and Oscillatory Bursting.International journal of molecular sciences · 2022Article
- Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination.Molecular neurodegeneration · 2022Review
- The effects of mesenchymal stem cells transplantation on A1 neurotoxic reactive astrocyte and demyelination in the cuprizone model.Journal of molecular histology · 2022Article
- Biochanin A Improves Memory Decline and Brain Pathology in Cuprizone-Induced Mouse Model of Multiple Sclerosis.Behavioral sciences (Basel, Switzerland) · 2022Article
- Dysregulated copper transport in multiple sclerosis may cause demyelination via astrocytes.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Markers of copper transport in the cingulum bundle in schizophrenia.Schizophrenia research · 2021Article
- Myelination- and immune-mediated MR-based brain network correlates.Journal of neuroinflammation · 2020Article
- Differential Susceptibility and Vulnerability of Brain Cells in C57BL/6 Mouse to Mitochondrial Dysfunction Induced by Short-Term Cuprizone Exposure.Frontiers in neuroanatomy · 2020Article
- Relationship of Iron Metabolism and Short-Term Cuprizone Treatment of C57BL/6 Mice.International journal of molecular sciences · 2019Article
- Mitochondrial Impairment in Oligodendroglial Cells Induces Cytokine Expression and Signaling.Journal of molecular neuroscience : MN · 2019Article
- Five Decades of Cuprizone, an Updated Model to Replicate Demyelinating Diseases.Current neuropharmacology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
A growing body of evidence suggests the involvement of inflammatory processes in the pathophysiology of schizophrenia. Four- to 8-week exposure to cuprizone, a copper chelator, causes robust demyelination and has been used to build a model for multiple sclerosis. In contrast, we report here the effects of 1-week cuprizone exposure in mice. This short-term cuprizone exposure elicits behavioral changes that include augmented responsiveness to methamphetamine and phencyclidine, as well as impaired working memory. The cellular effects of 1-week cuprizone exposure differ substantially from the longer-term exposure; perturbation of astrocytes and microglia is induced without any sign of demyelination. Furthermore, the proinflammatory cytokine interleukin-6 was significantly up-regulated in glial fibrillary acidic protein (GFAP)-positive cells. We propose that this cuprizone short-term exposure may offer a model to study some aspects of biology relevant to schizophrenia and related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.